These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31642804)

  • 1. Value in Health: How It Is Defined and Used in Priority Setting and Pricing in Norway.
    Melberg HO
    Healthc Pap; 2019 Oct; 18(3):22-28. PubMed ID: 31642804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new proposal for priority setting in Norway: Open and fair.
    Ottersen T; Førde R; Kakad M; Kjellevold A; Melberg HO; Moen A; Ringard Å; Norheim OF
    Health Policy; 2016 Mar; 120(3):246-51. PubMed ID: 26851991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indication-specific pricing of pharmaceuticals in the US healthcare system.
    Pearson SD; Dreitlein WB; Henshall C; Towse A
    J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Value of Medicines: A Crucial but Vague Concept.
    Antoñanzas F; Terkola R; Postma M
    Pharmacoeconomics; 2016 Dec; 34(12):1227-1239. PubMed ID: 27444306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards cost-value analysis in health care?
    Nord E
    Health Care Anal; 1999; 7(2):167-75. PubMed ID: 15968970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Does budget consequences control Norwegian reimbursement priorities?].
    Robberstad B; Askildsen JE; Norheim OF
    Tidsskr Nor Laegeforen; 2013 Sep; 133(17):1841-3. PubMed ID: 24042299
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?
    Lauenroth VD; Stargardt T
    Value Health; 2017; 20(7):927-935. PubMed ID: 28712622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pricing and reimbursement of pharmaceuticals. A new culture for the community pharmacist.
    Moen E; Toverud EL; Grund J; Brinchmann S
    Pharm World Sci; 1998 Jun; 20(3):107-12. PubMed ID: 9618733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operationalizing value-based pricing of medicines : a taxonomy of approaches.
    Sussex J; Towse A; Devlin N
    Pharmacoeconomics; 2013 Jan; 31(1):1-10. PubMed ID: 23329588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicines with one seller and many buyers: strategies to increase the power of the payer.
    Rintoul A; Colbert A; Garner S; Kotwani A; Vogler S; Bouvy J; Hill A
    BMJ; 2020 May; 369():m1705. PubMed ID: 32434753
    [No Abstract]   [Full Text] [Related]  

  • 12. Reference pricing and price negotiations for innovative new drugs : viable policies in the long term?
    Gandjour A
    Pharmacoeconomics; 2013 Jan; 31(1):11-4. PubMed ID: 23329589
    [No Abstract]   [Full Text] [Related]  

  • 13. Priority setting in health care: unburdening from the burden of disease.
    Mooney G; Irwig L; Leeder S
    Aust N Z J Public Health; 1997 Dec; 21(7):680-1. PubMed ID: 9489181
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceutical priority setting and the use of health economic evaluations: a systematic literature review.
    Erntoft S
    Value Health; 2011 Jun; 14(4):587-99. PubMed ID: 21669384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovative Contracting for Pharmaceuticals and Medicaid's Best-Price Rule.
    Sachs R; Bagley N; Lakdawalla DN
    J Health Polit Policy Law; 2018 Feb; 43(1):5-18. PubMed ID: 28972020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Priority setting and rationing of pharmaceuticals - an experimental analysis of discussion processes].
    Aumann I; Litzkendorf S; Damm K; von der Schulenburg JMG
    Z Evid Fortbild Qual Gesundhwes; 2017 Aug; 125():3-13. PubMed ID: 28694036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-utility analysis as a mechanism for allocation of health care resources: a review of the debate].
    Pinho MM; Veiga PA
    Cad Saude Publica; 2009 Feb; 25(2):239-50. PubMed ID: 19219231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical Reference Pricing: Does It Have a Future in the U.S.?
    Robinson JC
    Issue Brief (Commonw Fund); 2018 Sep; 2018():1-6. PubMed ID: 30199167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priority setting in health care: an axiomatic bargaining approach.
    Clark D
    J Health Econ; 1995 Aug; 14(3):345-60. PubMed ID: 10145139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.